Public Sector Pension Investment Board Increases Stock Position in Glaukos Co. (NYSE:GKOS)

Public Sector Pension Investment Board raised its holdings in Glaukos Co. (NYSE:GKOS) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,605 shares of the medical instruments supplier’s stock after purchasing an additional 5,700 shares during the quarter. Public Sector Pension Investment Board owned 0.21% of Glaukos worth $15,191,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in GKOS. Values First Advisors Inc. purchased a new stake in shares of Glaukos during the 3rd quarter worth approximately $25,000. Harvest Fund Management Co. Ltd boosted its stake in shares of Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Glaukos by 68.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 486 shares in the last quarter. Fifth Third Wealth Advisors LLC purchased a new stake in shares of Glaukos during the 2nd quarter worth approximately $187,000. Finally, KBC Group NV raised its position in shares of Glaukos by 16.2% during the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after purchasing an additional 201 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Up 1.4 %

Shares of NYSE GKOS opened at $142.69 on Friday. The firm has a fifty day moving average of $133.56 and a 200-day moving average of $124.39. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52-week low of $59.58 and a 52-week high of $146.86. The stock has a market capitalization of $7.87 billion, a PE ratio of -47.25 and a beta of 1.02.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. During the same period in the prior year, the company earned ($0.50) EPS. The firm’s revenue was up 23.9% on a year-over-year basis. On average, analysts anticipate that Glaukos Co. will post -1.96 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on GKOS shares. Wells Fargo & Company lifted their price objective on Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Piper Sandler set a $140.00 price objective on Glaukos in a research report on Thursday, October 17th. BTIG Research lifted their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Needham & Company LLC boosted their price target on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and an average price target of $135.45.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the sale, the director now owns 32,336 shares in the company, valued at $4,225,345.12. This represents a 8.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at approximately $14,198,425.93. This trade represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.